CLAIMS

1. Use of a composition comprising angiotensin II in the manufacture of a medicament for the treatment of hypotension, wherein the medicament is to be administered to a human patient receiving a catecholamine and having an initial mean arterial pressure; and

wherein after a period of time, the patient's mean arterial pressure is measured; and if the measured mean arterial pressure is at or above 75 mm Hg, the rate at which catecholamine is administered to the patient is decreased.

2. The use of claim 1, wherein if the measured mean arterial pressure is below 75 mm Hg, the rate of administering the medicament is increased.

3. Use of a composition comprising angiotensin II in the manufacture of a medicament for the treatment of hypotension, wherein the medicament is to be administered to a human patient receiving a catecholamine and having an initial mean arterial pressure; and

wherein after a period of time, the patient's mean arterial pressure is measured; and if the measured mean arterial pressure is at least 10 mm Hg higher than the initial mean arterial pressure, the rate at which catecholamine is administered to the patient is decreased.

4. The use of claim 3, wherein if the measured mean arterial pressure is less than 5 mm Hg higher than the initial mean arterial pressure, the rate of administering the medicament is increased.

5. The use of any preceding claim, wherein the catecholamine is dopamine, norepinephrine, or epinephrine.

6. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.1 μg/kg/min of norepinephrine.

7. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.2 μg/kg/min of norepinephrine.

8. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.5 μg/kg/min of norepinephrine.

9. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 1.0 μg/kg/min of norepinephrine.

10. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.1 μg/kg/min of epinephrine.

11. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.2 μg/kg/min of epinephrine.

12. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 0.5 μg/kg/min of epinephrine.

13. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 1.0 μg/kg/min of epinephrine.

14. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 5 μg/kg/min of dopamine.

15. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 15 μg/kg/min of dopamine.

16. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 20 μg/kg/min of dopamine.

17. The use of any one of claims 1-5, wherein, prior to administering the medicament, the patient is receiving at least 25 μg/kg/min of dopamine.

18. The use of any one of claims 1-5, wherein the patient has a cardiovascular sequential organ failure assessment score ("SOFA score") of 3 or 4.

19. The use of claim 18, wherein the patient has a cardiovascular SOFA score of 4.

20. The use of any one of claims 1-19, wherein the initial mean arterial pressure is 65 mm Hg or less.

21. The use of any one of claims 1-19, wherein the initial mean arterial pressure is 70 mm Hg or less.

22. The use of any one of the preceding claim, wherein the period of time is less than two hours.

23. The use of claim 22, wherein the period of time is about one hour or less.

24. The use of any one of claims 1-23, wherein the rate at which the catecholamine is administered is decreased by at least 15%.

25. The use of any one of claims 1-23, wherein the rate at which the catecholamine is administered is decreased by at least 60%.

26. The use of any one of claims 1-25, wherein the medicament is to be administered at an initial rate greater than or equal to 5 ng/kg/min.

27. The use of any one of claims 1-25, wherein the medicament is to be administered at an initial rate of about 20 ng/kg/min.

28. The use of any one of claims 1-25, wherein the medicament is to be administered at an initial rate of about 40 ng/kg/min.

29. The use of any one of claims 1-28, further comprising the step of increasing the rate at which the medicament is to be administered.

30. The use of claim 29, wherein the rate at which the medicament is to be administered is increased to a final rate of less than or equal to 40 ng/kg/min.

31. The use of claim 29 or 30, wherein the rate at which the medicament is to be administered is increased over the course of no more than six hours.

32. The use of any one of claims 1-28, further comprising the step of decreasing the rate at which the medicament is to be administered.

33. The use of claim 32, wherein the rate at which the medicament is to be administered is decreased to a final rate of less than or equal to 5 ng/kg/min.

34. The use of claim 32 or 33, wherein the rate at which the medicament is to be administered is decreased over the course of no more than six hours.

35. The use of any one of claims 1-34, wherein the medicament is to be administered continuously for at least 1-11 days, such as 1-6 days.

36. The use of any one of claims 1-34, wherein the medicament is to be administered continuously over a period of time selected from less than 6 hours; from 6 hours to 24 hours; or at least 24 hours.

37. The use of any one of claims 1-34, wherein the medicament is to be administered until the mean arterial pressure of the patient can be maintained at or above 70 mm Hg with less than 0.1 μg/kg/min norepinephrine, less than 0.1 μg/kg/min epinephrine, or less than 15 μg/kg/min dopamine.

38. The use of any one of the preceding claims, wherein the angiotensin II has the sequence set forth in SEQ ID NO: l , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8.

39. The use of claim 38, wherein the angiotensin II has the sequence set forth in SEQ ID NO: 1.

40. The use of any one of claims 1-37, wherein the angiotensin II is 5-L-valinc angiotensin II; l-L-asparaginc-5-L-valinc angiotensin II; l-L-asparaginc-5-L-isolcucinc angiotensin II; or l-L-asparaginc-5-L-isolcucinc angiotensin II.

41. The use of claim 40, wherein the angiotensin II is 5-L-isolcucinc angiotensin II.

42. The use of any one of the preceding claims, wherein the medicament comprises angiotensin II at a concentration of about 2.5 mg/mL.

43. The use of any one of the preceding claims, wherein the medicament further comprises mannitol as an excipient.

44. The use of claim 43, wherein the medicament comprises mannitol at a concentration of about 12.5 mg/mL.

45. The use of any one of the preceding claims, wherein the medicament is suitable for parenteral administration.

46. The use of claim 45, wherein the parenteral administration is injection or intravenous infusion.

47. The use of claim 46, wherein the parenteral administration is intravenous infusion.

48. The use of any one of the preceding claims, wherein the patient has sepsis.

49. The use of claim 48, wherein the patient has septic shock.

50. The use of any one of the preceding claims, wherein the patient has distributive shock.

51. The use of any one of the preceding claims, wherein the patient has cardiogenic shock.